 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| The Company |
|---|
| Management |
| Board of Directors |
The CompanyArrayXpress is a laboratory services company that designs, produces and analyzes microarrays. As microarray technology exploded onto the scene in recent years, the need for quality-driven service providers in the industry became apparent. ArrayXpress was founded with the vision of providing a complete solution for anyone needing to utilize microarrays in diagnostics and other research to identify genes regulating phenotypic traits of interest.The company uses its patented methods and techniques to generate the highest quality microarray data and results available in the industry – all at a lower cost than otherwise available. Additionally, through a strategic relationship with SAS Institute, ArrayXpress is able to provide an extremely powerful and unparalleled statistical analysis of the results of its microarray experiments. ArrayXpress was founded in January 2003 as a Delaware “C” corporation and maintains its principal place of business in Raleigh, North Carolina. Top
Chief Scientific Officer - Leonel M. van Zyl, Ph.D.; is highly accredited in the study and use of microarray technology. Len has over 10 years of experience in studying gene expression and is a professor at NC State University in the Forestry Biotechnology Group of the Department of Forestry. Len received his Ph.D. in Microbiology and Genetics from the University of the Orange Free State in the Republic of South Africa.
ArrayXpress has five members of its Board of Directors. Internal Directors include Michael Zapata and Len van Zyl. The company currently has the following three external Directors: Stephen K. Markham, Ph.D.; Director, is an experienced entrepreneur and financial manager who has served as a board member for LIPSinc, LipoScience, and Kyma. Steve is a tenured faculty member in the Department of Business Management at NC State University. He specializes in technology management and product development, and serves on the executive committee of the Product Development and Management Association. Athanasios (Thanos) Maroglou, Ph.D.; Director, has worked for over 20 years as a senior executive with large and small life science companies. Currently, Dr. Maroglou is Vice President of Business Development of Chimerix, Inc., a drug discovery and development company focused on antiviral drugs. He also is a Board Member for Southeast Techlnventures, Inc. and NIRvana Pharmaceuticals, Inc. Previously, Dr. Athanasios Maroglou was President and co-founder of Ercole Biotech, Inc., a drug discovery company that develops splice switching drugs and an Associate with A.M. Pappas and Associates, a venture capital company. Prior to Ercole Biotech, Dr. Maroglou was the Vice President of Project Management of Paradigm Genetics, Inc. a functional genomics company that went public in 2000. Spending 14 years with E.I. DuPont DeNemours, Inc., Dr. Maroglou held positions of increasing management responsibility in research, manufacturing, and business. Dr. Athanasios Maroglou earned a B.Sc. and Ph.D. in Chemical Engineering from the University of Birmingham, UK.
Caroline Popper, MD, MPH; Director, is an experienced biotech board member and corporate officer. Caroline is currently a Senior Vice President of bioMerieux. She is a founder and president of two Florida biotechnology companies and an officer in two others. She has also been the Chief Business Officer of MDS Proteomics and has held a number of VP, GM, and Director positions at Becton Dickinson.
|
Superior Quality
The best raw data, experimental results
and analysis
available in the industry
Complete Solution
The first and still the best commercial one-stop shop for microarray services
Fully Customizable
Any size, any organism, any method, any microarray experiment
Lower Cost
Save now (lower project cost) and save later (lower downstream costs)
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
